Treatment of essential hypertension in adults and children aged 6 to < 18 years.
Treatment of heart failure (NYHA class II-III) in patients with left ventricular systolic dysfunction (ejection fraction ≤ 40%) to reduce cardiovascular death and to reduce heart failure hospitalizations. Combination therapy with an ACE inhibitor compared with therapy with either type of agent alone, but not supported, or when patients were intolerant of ACE inhibitors.
- 8 mg once daily. Most of the effect is attained within 4 weeks. In some patients whose blood pressure is not adequately controlled, the dose can be increased to 16 mg once daily and to a maximum of 32 mg once daily.
- Patients with intravascular volume depletion: An initial dose of 4 mg may be considered in patients at risk for hypotension.
- In patients with hepatic impairment: An initial dose of 4 mg once daily is recommended in patients with mild to moderate hepatic impairment. Candesartan is contraindicated in patients with severe hepatic impairment or cholestasis.
- In patients with renal impairment: An initial dose of 4 mg once daily, including for patients on haemodialysis. There is limited experience in patients with very severe or end-stage renal impairment (Clcr < 15 ml/min).
Child 6–18 years:
- < 50 kg: Initially 4 mg once daily (lower dose in intravascular volume depletion), adjusted according to response; maximum 8 mg once daily.
- ≥ 50 kg: Initially 4 mg once daily (lower dose in intravascular volume depletion), adjusted according to response; maximum 16 mg once daily.
The usual initial dose of candesartan is 4 mg once daily. The dose should be doubled at intervals of not less than 2 weeks up to 32 mg once daily (maximum dose) if tolerated.
Candesartan STELLA 16 mg is only administered orally.